NClip

Growth Hormones and Suppressants

3 min read

Growth Hormones and Suppressants

Key Points

  • Growth hormone (somatotropin axis) supports bone, muscle, and tissue growth through IGF-1 signaling.
  • Somatropin replacement is used for growth-hormone deficiency pathways and selected syndrome-specific indications.
  • Growth-hormone suppressants are used mainly for acromegaly or excess-growth-hormone states.
  • Octreotide/lanreotide (somatostatin analogs), bromocriptine (dopamine agonist), and pegvisomant (GH receptor antagonist) are common suppressants.
  • Core safety priorities are glucose variability, GI effects, injection-site reactions, hepatic/renal risk contexts, and neuro/mental-status monitoring.

Growth Hormone Replacement

Somatropin

  • Recombinant growth-hormone product used for failure to grow due to growth-hormone deficiency in pediatric and adult populations (and selected syndrome-specific protocols such as Prader-Willi pathways).
  • Increases IGF-1 signaling to support growth and anabolic tissue effects.
  • Typically administered by subcutaneous injection with individualized dosing.

Key interactions

  • Glucocorticoids may oppose growth-promoting effects.
  • Oral estrogen can alter growth-hormone response.
  • Insulin/oral diabetes medications may require adjustment because somatropin can increase blood glucose.

Common adverse effects

  • Injection-site reaction, rash, lipoatrophy, headache.
  • Thyroid-axis suppression and hyperglycemia risk.

Contraindication/caution profile

  • Active malignancy, critical illness, hypersensitivity.
  • Impaired glucose tolerance/diabetes risk contexts.
  • Closed epiphyses in pediatric growth pathways.

Growth Hormone Suppressants

Drug classes and examples

  • Somatostatin analogs: octreotide, lanreotide.
  • Dopamine agonists: bromocriptine.
  • Growth-hormone receptor antagonist: pegvisomant.

Typical uses

  • Acromegaly when surgery/radiation is inadequate or inappropriate.
  • Selected unresectable tumor syndromes with hormone-driven symptom burden.

Class-level adverse effects

  • GI symptoms: abdominal pain, nausea, vomiting, diarrhea.
  • Glucose dysregulation: hypo- or hyperglycemia.
  • Fatigue/weakness, vitamin B12 deficiency, injection-site reactions.
  • Organ risk amplification in severe hepatic or renal impairment contexts.

Notable agent-specific cues

  • Bromocriptine: can cause nausea, dizziness, drowsiness, constipation, and abdominal cramps; avoid in uncontrolled hypertension/hypersensitivity.
  • Lanreotide: interaction concerns include cyclosporine, bromocriptine, beta blockers; may cause cholelithiasis and GI symptoms.
  • Octreotide: can cause gallbladder abnormalities, bradycardia/arrhythmias, hypo- or hyperglycemia, and hypothyroidism; monitor closely in cholelithiasis history.
  • Pegvisomant: liver-test abnormalities and flu-like symptoms can occur; monitor hepatic safety cues.

Nursing Assessment and Monitoring

  • Verify diagnosis and treatment intent: replacement vs suppression.
  • Keep the medication list current and screen for hypersensitivity before each cycle.
  • Trend glucose and endocrine-lab patterns (including IGF-1 where ordered).
  • Monitor for toxicity cues: blurred vision, confusion, persistent GI symptoms, severe headache.
  • For octreotide/lanreotide pathways, monitor rhythm and gallbladder-related symptom cues when indicated.
  • Assess mental-health/neuropsychiatric status when symptom profile or concurrent therapies raise concern.

Patient Education

  • Take/administer exactly as prescribed; do not self-stop therapy abruptly.
  • Report worsening headache, confusion, persistent abdominal pain, severe nausea/vomiting, or injection-site inflammation.
  • Report mood/behavior changes and any worsening cardiometabolic symptoms promptly.
  • Keep follow-up visits and ordered lab draws for dose titration and safety monitoring.
  • Do not use these medications as acute rescue therapy for sudden respiratory distress.
  • endocrine-system - Hormonal regulation framework including GH axis physiology.
  • corticosteroids - Glucocorticoid interaction context that may blunt somatropin growth effects.
  • insulin - Glucose-management implications when GH-pathway drugs alter glycemic control.

Graph View

Backlinks